Korean Journal of Nephrology 1996;15(4):576-581.

신장 이식 환자에서 Trimethoprim Sulfamethexazole이 감염에 미치는 영향

백인규 , 강경원, 강종명 , 곽진영

Abstract

To determine the efficacy of long-term prophy- laxis with trimethoprim-sulfamethoxazole for preven- tion of bacterial infection following renal transplantion, we studied 66 cases of renal transplants performed in Hanyang University Hospital, Seoul, Korea from January 1993 to October 1994. For prophyaxis ceftezole was given 3.0g a day for 7 days from the day of operation and Trimethoprim-Sulfamethoxazole was given randomly from the day of operation. Patients took two tablets of Trimethoprim-Sulfame- thoxazole for 2 weeks and one tablet thereafter. Patients were classified into three groups (Group 1: patients taking medicine continously, Group 2: patients taking medicine during admission, Group 3: patients not taking medicine). Foley catheter was almost always removed on the 7th post operative day. We defined urinary tract infection (UTI) as bacteria or fungi were cultured at concentration of at least 100,000 organisms/ml of urine. 1) The mean age of patients were 37.7±10.1 in male and 35.6±10 in female, and male to female ratio was 1.8:l. 2) There occurred 29 cases of infections, 19 of these cases were urinary tract infection, 3 were blood infection, 5 were skin infection and 2 were unclassified. 3) The overall incidence of urinary tract infection was 28.8%. 4) Age didn't influence on the incidence of uri- nary tract infection. 5) There were no differences among rnale and female in the incidence of urinary tract infection. 6) There were no differences in overall incidences of UTI between TMP-SMZ treated group and non- treated group. 7) There were no differences in the blood con- centration of cyclosporine between TMP-SMZ trea- ted group and non-treated goup. 8) The graft rejection and the use of antilym- phocytic therapy didn't influence on the incidence of the urinary tract infection after renal transplantation. 9) We didn't observe the changes of BUN/Cr by the use of TMP-SMZ and the hematologic abnor- malities after 2 months of follow-up.